The σ1 receptor is a target for the development of cardioprotective drugs
Life Sciences · 2025
DOI: 10.1016/j.lfs.2025.124012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life Sciences, 2025. Verfasst von Leonid N Maslov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Research Institute, National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. Electronic address: maslov@cardio-tomsk.…. Hauptthemen laut MEDLINE: Receptors, sigma, Cardiotonic Agents. Die Arbeit nennt 100 Literaturangaben. Gefördert von: Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
BACKGROUND: In-hospital mortality in patients with acute myocardial infarction (AMI) is 4.6 % - 7.5 %. One of the causes of death is reperfusion cardiac injury (RCI). The most common cause of death in AMI is cardiogenic shock. Studying the cardiovascular effects of σ1-receptor agonists can contribute to the development of drugs for the treatment of RCI. METHODS: A search for relevant topical articles was performed using the PubMed database. FINDINGS: The σ1-receptor is expressed in cardiomyocytes and endothelial cells. The σ1-receptor was found in the cell membrane, the endoplasmic reticulum (ER), and mitochondria. It is coupled to the inositol triphosphate (IP3) receptor and ryanodine receptors in the ER. The σ1-receptor regulates Ca2+ transport in the ER and mitochondria. σ1-Receptor agonists increase contractility of isolated cardiomyocytes and the heart in vivo. Chronic activation of the σ1-receptor mitigates the development of pressure overload-induced adverse remodeling of the heart. Activation of the σ1-receptor inhibits apoptosis of cardiomyocytes in ischemia/reperfusion of the heart. σ1-Receptor stimulation promotes the activation of protein kinase C, Akt, NO-synthase, and heme oxygenase-1. Stimulation of σ1-receptor contributes to the closure of mitochondrial permeability pore. Presumably mitochondria are responsible for effects of σ1-receptor agonists. CONCLUSION: σ1-Receptor agonists may become the basis for the development of drugs for the treatment of AMI and cardiogenic shock and the prevention of adverse cardiac remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Research Institute, National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. Electronic address: maslov@cardio-tomsk.ru.
- Department of Medicine, Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
- Cardiology Research Institute, National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia; Siberian State Medical University, Tomsk, Russia.
- Cardiology Research Institute, National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
- Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
Förderung
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Maslov, L. N., Tsirulnikov, K., Slidnevskaya, A. S., Kilin, M., Kan, A., Grab, A. E., Gorbunov, A. S., & Singh, N. (2025). The σ1 receptor is a target for the development of cardioprotective drugs. Life Sciences. https://doi.org/10.1016/j.lfs.2025.124012
Vancouver
Maslov LN, Tsirulnikov K, Slidnevskaya AS, Kilin M, Kan A, Grab AE, et al. The σ1 receptor is a target for the development of cardioprotective drugs. Life Sciences. 2025. doi:10.1016/j.lfs.2025.124012
BibTeX
@article{Maslov2025,
author = {Maslov, Leonid N and Tsirulnikov, Kirill and Slidnevskaya, Alisa S and Kilin, Mikhail and Kan, Artur and Grab, Alexandr E and Gorbunov, Alexandr S and Singh, Nirmal},
title = {The σ1 receptor is a target for the development of cardioprotective drugs},
journal = {Life Sciences},
year = {2025},
doi = {10.1016/j.lfs.2025.124012}
}
EUVIMED